AntriaBio snaps up $12M in private placement deal

An image of text of the definition of diabetes
AntriaBio snags $12 million in funding for diabetes drug.

AntriaBio ($ANTB), a biopharma focused on developing novel extended release therapies, has raised $12 million in a private placement deal.

The company said funds raised in the transaction will be used for general corporate purposes including preparation for Phase 1 clinical studies for AB101, its injectable once-weekly basal insulin for patients with type 1 and type 2 diabetes.

The funding round was led by pH Pharma, an affiliate of SBI Investment Korea, a venture capital firm that was spun out of SoftBank.

Since being founded in 2013, the Colorado-based AntriaBio has raised about $35 million through equity financings. In the most recent financing deal, accredited investors and institutions paid $1.10 for one share of common stock and received warrants exercisable for five years at $1.65 for one share of common stock.

"The additional capital provides us with resources to further our development of AB101, as well as to advance other potential long-acting product candidates in our pipeline,” said Nevan Elam, chairman and CEO of AntriaBio, said in a statement.

AntriaBio’ touts AB101 as an injectable once-weekly basal insulin for type 1 and type 2 diabetes in what it estimates to be an $11 billion market where the current standard of care is a once-daily basal insulin injection.

-here’s the release

Related Articles: 
Midatech mulls options after oral insulin flunks PhIIa

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.